Form 4: Cocrystal Pharma Co-CEO Granted Stock Options

Cocrystal Pharma's President and Co-CEO, Sam Lee, was granted 49,229 non-qualified stock options with an exercise price of $1.1, vesting over time.

Summary

• Sam Lee, President and Co-CEO of Cocrystal Pharma, Inc. (COCP), was granted 49,229 non-qualified stock options.
• The options have an exercise price of $1.1 per share.
• The grant date was January 9, 2026, and the options are set to expire on January 9, 2036.
• Vesting will occur in two main phases: one-half (24,614.5 options) will vest on January 9, 2027, and the remaining half will vest in eight equal quarterly installments commencing on March 31, 2027.
• The vesting is contingent on Sam Lee's continued service as an officer of the Issuer on each applicable vesting date.
• The grant was made under the Issuer's 2025 Equity Incentive Plan and was approved by the Compensation Committee of the Board of Directors, making it exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. This is a routine executive compensation event. It's positive in that it aligns management incentives, but it's not a significant operational or financial announcement that would dramatically shift sentiment.

Positives

• Aligns management's interests with shareholder value through equity incentives, encouraging long-term performance.
• Represents a standard practice for executive compensation, indicating ongoing commitment from a key executive to the company's future.

Negatives

• Potential for future dilution if the options are exercised, although this is a common and expected aspect of equity compensation plans.

Future Outlook

The vesting schedule for the stock options extends through March 31, 2027, and beyond, contingent on Sam Lee's continued service, indicating a long-term incentive structure for a key executive and a commitment to future performance.

Management Comments

• The grant of non-qualified stock options was approved by the Issuer's Compensation Committee of the Board of Directors.

Industry Context

Equity grants to executives are a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key talent, aligning their performance with long-term company success and shareholder value creation. This practice is crucial in sectors requiring long development cycles and significant R&D investment.

Comparison to Industry Standards

• The grant of stock options as a component of executive compensation is a common practice across the pharmaceutical and biotechnology sectors, comparable to incentive structures seen at companies like Moderna, BioNTech, or Gilead Sciences, which frequently use equity to reward and retain leadership.
• The vesting schedule, with a portion vesting after one year and the remainder quarterly, is typical for executive equity awards, designed to ensure long-term commitment and performance, aligning with best practices for executive retention and motivation.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also benefits from increased alignment of executive interests with long-term share price performance.
• Employees: May signal stability in executive leadership and a commitment to long-term incentive programs within the company.

Next Steps

• Sam Lee's continued service as an officer of Cocrystal Pharma, Inc. to meet vesting conditions.
• Execution of the Issuer's form of Non-Qualified Stock Option Agreement.
• Vesting of options on January 9, 2027, and subsequent quarterly installments commencing March 31, 2027.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of stock options to a key executive, which is a standard component of executive compensation. While it aligns management's interests with shareholder value, it does not present new material information that would fundamentally alter the company's financial outlook or operational performance. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Cocrystal Pharma, COCP, Sam Lee, Stock Options, Equity Incentive Plan, Executive Compensation, Form 4, SEC Filing, Biotechnology, Pharmaceuticals